Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04607668
Title Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Trilaciclib

Age Groups: adult | senior
Covered Countries USA | ITA | ESP


No variant requirements are available.